{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:20:55Z","timestamp":1790677255725,"version":"4.1.0"},"reference-count":188,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00123","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T04:39:19Z","timestamp":1587530359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":178,"title":["Serum Biomarkers for Inflammatory Bowel Disease"],"prefix":"10.3389","volume":"7","author":[{"given":"Peng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoshi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.14309\/ctg.0000000000000015","article-title":"Mucosal healing is associated with the reduced disabling disease in Crohn's disease","volume":"10","author":"Huang","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/ajg.2012.127","article-title":"The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort","volume":"107","author":"Targownik","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4253\/wjge.v7.i7.670","article-title":"Gastrointestinal endoscopy biopsy derived proteomic patterns predict indeterminate colitis into ulcerative colitis and Crohn's colitis","volume":"7","author":"Ballard","year":"2015","journal-title":"World J Gastrointest Endosc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ibd.22951","article-title":"Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease?","volume":"19","author":"Ananthakrishnan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: part 1: diagnosis and Medical Management","volume":"11","author":"Gomoll\u00f3n","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/MIB.0000000000001143","article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn's disease","volume":"23","author":"Fernandes","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","article-title":"European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations","volume":"11","author":"Gionchetti","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/ecco-jcc\/jjx105","article-title":"Corrigendum: third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.3390\/ijms19082244","article-title":"Anti-TNF therapy in Crohn's Disease","volume":"19","author":"Adegbola","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1753191073","DOI":"10.1177\/2040622319899297","article-title":"Emerging treatments for inflammatory bowel disease","volume":"11","author":"Hazel","year":"2020","journal-title":"Ther Adv Chronic Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of Ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/ibd\/izz078","article-title":"Challenges in IBD research: precision medicine","volume":"25","author":"Denson","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory Markers in IBD: Useful, Magic, or Unnecessary Toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut."},{"key":"B21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0171-2985(11)80509-7","article-title":"A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease","volume":"181","author":"Rump","year":"1990","journal-title":"Immunobiology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1080\/00365521.2017.1344875","article-title":"The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient","volume":"52","author":"Smids","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gut.47.4.487","article-title":"Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics","volume":"47","author":"Vasiliauskas","year":"2000","journal-title":"Gut."},{"key":"B24","doi-asserted-by":"publisher","first-page":"640835","DOI":"10.1155\/2012\/640835","article-title":"Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease","volume":"2012","author":"Pavlidis","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-230X-12-102","article-title":"Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease","volume":"12","author":"Bogdanos","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1097\/MIB.0000000000000564","article-title":"Pancreatic autoantibodies against CUZD1 and GP2 are associated with distinct clinical phenotypes of Crohn's disease","volume":"21","author":"Michaels","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ecco-jcc\/jjz012","article-title":"Identification of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn's disease","volume":"13","author":"Deutschmann","year":"2019","journal-title":"J Crohns Colitis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1097\/MIB.0b013e318281f506","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease","volume":"19","author":"Gathungu","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.3748\/wjg.v21.i22.6952","article-title":"Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease","volume":"21","author":"Sipeki","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ibd.20985","article-title":"Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease","volume":"16","author":"Joossens","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ecco-jcc\/jjv063","article-title":"Association of anti-glycan antibodies and inflammatory bowel disease course","volume":"9","author":"Paul","year":"2015","journal-title":"J Crohns Colitis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.11613\/BM.2013.006","article-title":"Serological markers of inflammatory bowel disease","volume":"23","author":"Kuna","year":"2013","journal-title":"Biochem Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/jgh.13677","article-title":"Serologic antibodies in relation to outcome in postoperative Crohn's disease","volume":"32","author":"Hamilton","year":"2017","journal-title":"J Gastroenterol Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/MEG.0000000000000102","article-title":"Serum antibodies to microbial antigens for Crohn's disease progression: a meta-analysis","volume":"26","author":"Xiong","year":"2014","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.12661","article-title":"Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"30","author":"Kevans","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/MIB.0b013e318281f2a1","article-title":"Serum antibodies associated with complex inflammatory bowel disease","volume":"19","author":"Elkadri","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000442934","article-title":"ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of inflammatory bowel disease?","volume":"34","author":"Zhou","year":"2016","journal-title":"Dig Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ibd.21046","article-title":"Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior","volume":"16","author":"Rieder","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1097\/MIB.0000000000000926","article-title":"Distinct Anti-IFI16 and anti-GP2 antibodies in inflammatory bowel disease and their variation with infliximab therapy","volume":"22","author":"Caneparo","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1097\/MIB.0000000000000135","article-title":"Role of biomarkers in the study and management of inflammatory bowel disease: a \u201cnonsystematic\u201d review","volume":"20","author":"Sachar","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-017-0619-4","article-title":"Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease","volume":"17","author":"Tran","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.26355\/eurrev_201901_16893","article-title":"Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis","volume":"23","author":"Nakov","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-012-1389-0","article-title":"Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis","volume":"69","author":"Lacruz-Guzman","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/00365521.2017.1339825","article-title":"Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease","volume":"52","author":"Billiet","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1097\/MIB.0000000000001172","article-title":"Serum interleukin 9 levels predict disease severity and the clinical efficacy of infliximab in patients with Crohn's disease","volume":"23","author":"Feng","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.3748\/wjg.v22.i41.9104","article-title":"Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy","volume":"22","author":"Baird","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ecco-jcc\/jju008","article-title":"Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C","volume":"9","author":"Magnusson","year":"2015","journal-title":"J Crohns Colitis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/ibd\/izy358","article-title":"Multiple cytokine profiling: a new model to predict response to tumor necrosis factor antagonists in ulcerative colitis patients","volume":"25","author":"Obraztsov","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14235","article-title":"Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients","author":"Bertani","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/00042737-199710000-00004","article-title":"A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease","volume":"9","author":"Louis","year":"1997","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B53","first-page":"936","article-title":"Differential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis","volume":"11","author":"Luo","year":"2018","journal-title":"Int J Clin Exp Pathol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.3748\/wjg.v22.i19.4716","article-title":"Plasma long noncoding RNA expression profile identified by microarray in patients with Crohn's disease","volume":"22","author":"Chen","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3892\/mmr.2017.8118","article-title":"KIF9AS1, LINC01272 and DIO3OS lncRNAs as novel biomarkers for inflammatory bowel disease","volume":"17","author":"Wang","year":"2018","journal-title":"Mol Med Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s10620-012-2127-2","article-title":"Serum metabolic profiling in inflammatory bowel disease","volume":"57","author":"Williams","year":"2012","journal-title":"Dig Dis Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e31131","DOI":"10.1371\/journal.pone.0031131","article-title":"Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease","volume":"7","author":"Hisamatsu","year":"2012","journal-title":"PLoS ONE."},{"key":"B58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00011-011-0340-7","article-title":"GC\/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis","volume":"60","author":"Ooi","year":"2011","journal-title":"Inflamm Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11306-017-1311-y","article-title":"Alterations in lipid, amino acid, and energy metabolism distinguish Crohn's disease from ulcerative colitis and control subjects by serum metabolomic profiling","volume":"14","author":"Scoville","year":"2018","journal-title":"Metabolomics."},{"key":"B60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ecco-jcc\/jjw158","article-title":"Faecal and serum metabolomics in paediatric inflammatory bowel disease","volume":"11","author":"Kolho","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bcp.2006.12.019","article-title":"Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling","volume":"73","author":"Meuwis","year":"2007","journal-title":"Biochem Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e212300","DOI":"10.1371\/journal.pone.0212300","article-title":"Correction: exploration of serum proteomic profiling and diagnostic model that differentiate Crohn's disease and intestinal tuberculosis","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/ibd\/izy326","article-title":"Targeted analysis of serum proteins encoded at known inflammatory bowel disease risk loci","volume":"25","author":"Drobin","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00011-009-0016-8","article-title":"Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?","volume":"58","author":"Frol'Ova","year":"2009","journal-title":"Inflamm Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e227306","DOI":"10.1371\/journal.pone.0227306","article-title":"Serum galectins as potential biomarkers of inflammatory bowel diseases","volume":"15","author":"Yu","year":"2020","journal-title":"PLOS ONE."},{"key":"B67","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ecco-jcc\/jjy025","article-title":"Role of vitamin D in the natural history of inflammatory bowel disease","volume":"12","author":"Nielsen","year":"2018","journal-title":"J Crohns Colitis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/0148607113504002","article-title":"Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-alpha therapy in inflammatory bowel diseases","volume":"38","author":"Zator","year":"2014","journal-title":"J Parenter Enteral Nutr."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/MIB.0000000000000697","article-title":"The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study","volume":"22","author":"Santos-Antunes","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MIB.0000000000000588","article-title":"Role of vitamin D in infliximab-induced remission in adult patients with Crohn's Disease","volume":"22","author":"Reich","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/14728222.2019.1677608","article-title":"Oncostatin M as a new diagnostic, prognostic and therapeutic target in Inflammatory Bowel Disease (IBD)","volume":"23","author":"Verstockt","year":"2019","journal-title":"Expert Opin Ther Targets."},{"key":"B73","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/gut.30.5.627","article-title":"Plasma fibronectin in Crohn's disease","volume":"30","author":"Allan","year":"1989","journal-title":"Gut"},{"key":"B74","first-page":"231","article-title":"Assessment of plasma fibronectin in Crohn's disease","volume":"38","author":"Verspaget","year":"1991","journal-title":"Hepatogastroenterology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/jcp.56.11.817","article-title":"Serum laminin and collagen IV in inflammatory bowel disease","volume":"56","author":"Koutroubakis","year":"2003","journal-title":"J Clin Pathol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"643645","DOI":"10.1155\/2014\/643645","article-title":"Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases","volume":"2014","author":"Matusiewicz","year":"2014","journal-title":"Dis Mark."},{"key":"B77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-230X-8-55","article-title":"Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease","volume":"8","author":"Kapsoritakis","year":"2008","journal-title":"BMC Gastroenterol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e13002","DOI":"10.1111\/eci.13002","article-title":"Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases","volume":"48","author":"Carbone","year":"2018","journal-title":"Eur J Clin Invest."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11605-007-0233-9","article-title":"Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease","volume":"11","author":"De Simone","year":"2007","journal-title":"J Gastrointest Surg."},{"key":"B80","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/2050640616640160","article-title":"Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease","volume":"4","author":"Giuffrida","year":"2016","journal-title":"United European Gastroenterol J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.cgh.2018.09.008","article-title":"Association between plasma level of collagen type III alpha 1 chain and development of strictures in pediatric patients with Crohn's disease","volume":"17","author":"Ballengee","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e170506","DOI":"10.1371\/journal.pone.0170506","article-title":"Serum glycoproteome profiles for distinguishing intestinal fibrosis from inflammation in Crohn's disease","volume":"12","author":"Stidham","year":"2017","journal-title":"PLoS ONE."},{"key":"B83","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/00054725-200409000-00011","article-title":"Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease","volume":"10","author":"Di Sabatino","year":"2004","journal-title":"Inflamm Bowel Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/j.1440-1746.2007.05121.x","article-title":"Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease","volume":"23","author":"Erzin","year":"2008","journal-title":"J Gastroenterol Hepatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00384-002-0446-z","article-title":"Increased serum levels of YKL-40 in patients with inflammatory bowel disease","volume":"18","author":"Koutroubakis","year":"2003","journal-title":"Int J Colorectal Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/MIB.0000000000000004","article-title":"The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients","volume":"20","author":"Algaba","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MOG.0000000000000076","article-title":"Serological Studies in Inflammatory Bowel Disease: How Important Are They?","volume":"30","author":"Papp","year":"2014","journal-title":"Curr Opin Gastroenterol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3748\/wjg.v22.i3.1304","article-title":"Antibody markers in the diagnosis of inflammatory bowel disease","volume":"22","author":"Mitsuyama","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/00365521.2016.1205130","article-title":"Anti-food and anti-microbial IgG subclass antibodies in inflammatory bowel disease","volume":"51","author":"Jansen","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1572-0241.2001.03613.x","article-title":"Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease","volume":"96","author":"Peeters","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1053\/j.gastro.2015.08.006","article-title":"Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases","volume":"149","author":"Dubinsky","year":"2015","journal-title":"Gastroenterology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"185416","DOI":"10.1155\/2014\/185416","article-title":"Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies","volume":"2014","author":"Schulte-Pelkum","year":"2014","journal-title":"J Immunol Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ibd.21817","article-title":"Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels","volume":"18","author":"Vasseur","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1365-2036.2004.02258.x","article-title":"Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features","volume":"20","author":"Annese","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.3748\/wjg.v19.i37.6207","article-title":"Inflammatory bowel disease serology in Asia and the West","volume":"19","author":"Prideaux","year":"2013","journal-title":"World J Gastroenterol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1053\/gast.2002.32980","article-title":"The value of serologic markers in indeterminate colitis: a prospective follow-up study","volume":"122","author":"Joossens","year":"2002","journal-title":"Gastroenterology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/j.1572-0241.2006.00840.x","article-title":"Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease","volume":"101","author":"Reese","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.pathol.2019.07.002","article-title":"The significance of ANCA positivity in patients with inflammatory bowel disease","volume":"51","author":"Lee","year":"2019","journal-title":"Pathology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.crohns.2012.10.011","article-title":"Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2","volume":"7","author":"Komorowski","year":"2013","journal-title":"J Crohns Colitis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4161\/gmic.1.6.14078","article-title":"Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity","volume":"1","author":"Ohno","year":"2010","journal-title":"Gut Microbes."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","article-title":"Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses","volume":"189","author":"Werner","year":"2012","journal-title":"J Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cca.2014.12.010","article-title":"Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA","volume":"441","author":"Pavlidis","year":"2015","journal-title":"Clin Chim Acta."},{"key":"B103","doi-asserted-by":"publisher","first-page":"683824","DOI":"10.1155\/2013\/683824","article-title":"The novel Crohn's disease marker anti-GP2 antibody is associated with ileocolonic location of disease","volume":"2013","author":"Somma","year":"2013","journal-title":"Gastroenterol Res Pract."},{"key":"B104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/B978-0-12-407681-5.00006-4","article-title":"Glycoprotein 2 antibodies in Crohn's disease","volume":"60","author":"Roggenbuck","year":"2013","journal-title":"Adv Clin Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjv087","article-title":"Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn's patients: the importance of specific target antigens [GP2 and CUZD1]","volume":"9","author":"Papp","year":"2015","journal-title":"J Crohns Colitis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1515\/cclm-2015-0376","article-title":"Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies","volume":"54","author":"Pavlidis","year":"2016","journal-title":"Clin Chem Lab Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"127","DOI":"10.15403\/jgld.2014.1121.232.sg1","article-title":"Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease","volume":"23","author":"Gross","year":"2014","journal-title":"J Gastrointestin Liver Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41598-017-18622-1","article-title":"Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis","volume":"8","author":"Tornai","year":"2018","journal-title":"Sci Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e194166","DOI":"10.1371\/journal.pone.0194166","article-title":"Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients","volume":"13","author":"Kovacs","year":"2018","journal-title":"PLoS ONE."},{"key":"B110","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ibd.22862","article-title":"Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis","volume":"18","author":"Kaul","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet."},{"key":"B113","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","article-title":"Non-coding RNAs as drug targets","volume":"16","author":"Matsui","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","article-title":"Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches","volume":"96","author":"Beermann","year":"2016","journal-title":"Physiol Rev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ibd\/izx013","article-title":"Long ncRNA landscape in the ileum of treatment-naive early-onset Crohn disease","volume":"24","author":"Haberman","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/cei.12104","article-title":"Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease","volume":"173","author":"Iborra","year":"2013","journal-title":"Clin Exp Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e2703","DOI":"10.1097\/MD.0000000000002703","article-title":"Circulating microRNA223 is a new biomarker for inflammatory bowel disease","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine."},{"key":"B118","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.crohns.2012.02.006","article-title":"Circulating MicroRNA in inflammatory bowel disease","volume":"6","author":"Paraskevi","year":"2012","journal-title":"J Crohn's Colitis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ibd.21450","article-title":"Peripheral blood MicroRNAs distinguish active ulcerative colitis and Crohn's disease","volume":"17","author":"Wu","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MPG.0b013e31822200cc","article-title":"Circulating MicroRNA is a biomarker of pediatric Crohn disease","volume":"53","author":"Zahm","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/ibd\/izy046","article-title":"Circulating and Fecal microRNAs as biomarkers for inflammatory bowel diseases","volume":"24","author":"Schonauen","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/MIB.0000000000000285","article-title":"Overexpression of miR-595 and miR-1246 in the Sera of Patients with Active Forms of inflammatory bowel disease","volume":"21","author":"Krissansen","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/apt.15159","article-title":"Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease","volume":"49","author":"Chen","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1042\/CS20140048","article-title":"In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts","volume":"127","author":"Nijhuis","year":"2014","journal-title":"Clin Sci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1097\/MIB.0000000000000443","article-title":"Low serum levels of MicroRNA-19 are associated with a stricturing Crohn's disease phenotype","volume":"21","author":"Lewis","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nri2708","article-title":"Physiological and pathological roles for microRNAs in the immune system","volume":"10","author":"O'Connell","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13059-016-0901-8","article-title":"Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease","volume":"17","author":"Wang","year":"2016","journal-title":"Genome Biol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3389\/fmicb.2017.01896","article-title":"MicroRNAs-based inter-domain communication between the host and members of the gut microbiome","volume":"8","author":"Williams","year":"2017","journal-title":"Front Microbiol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.gastro.2013.10.021","article-title":"Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology."},{"key":"B130","doi-asserted-by":"publisher","first-page":"e2699","DOI":"10.1038\/cddis.2017.76","article-title":"Upregulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3","volume":"8","author":"Li","year":"2017","journal-title":"Cell Death Dis."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/MIB.0000000000000288","article-title":"MicroRNAs in inflammatory bowel diseases: paradoxes and possibilities","volume":"21","author":"Whiteoak","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1053\/j.gastro.2008.07.068","article-title":"MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha","volume":"135","author":"Wu","year":"2008","journal-title":"Gastroenterology."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2325162","DOI":"10.1155\/2016\/2325162","article-title":"Possible biomarkers in blood for crohn's disease: oxidative stress and micrornas-current evidences and further aspects to unravel","volume":"2016","author":"Moret-Tatay","year":"2016","journal-title":"Oxid Med Cell Longev."},{"key":"B134","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.intimp.2018.09.007","article-title":"MiR-155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via influencing the differentiation of Th17 cells by Jarid2","volume":"64","author":"Liu","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/jcp.27173","article-title":"MiRNAs and inflammatory bowel disease: an interesting new story","volume":"234","author":"Moein","year":"2019","journal-title":"J Cell Physiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/MIB.0000000000001086","article-title":"Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with inflammatory bowel disease","volume":"23","author":"Thorlacius-Ussing","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.dld.2017.08.003","article-title":"The contribution of long non-coding RNAs in inflammatory bowel diseases","volume":"49","author":"Zacharopoulou","year":"2017","journal-title":"Dig Liver Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2017.01.115","article-title":"MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease","volume":"486","author":"Chen","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"B139","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/MIB.0000000000000691","article-title":"Ulcerative colitis-associated long noncoding RNA, BC012900, regulates intestinal epithelial cell apoptosis","volume":"22","author":"Wu","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"17351","DOI":"10.1002\/jcp.28355","article-title":"Integrative analysis of OIP5-AS1\/HUR1 to discover new potential biomarkers and therapeutic targets in multiple sclerosis","volume":"234","author":"Gharesouran","year":"2019","journal-title":"J Cell Physiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.vph.2018.10.001","article-title":"Role of flow-sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis","volume":"114","author":"Kumar","year":"2019","journal-title":"Vascul Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"7243968","DOI":"10.1155\/2017\/7243968","article-title":"Long noncoding RNAs as biomarkers in cancer","volume":"2017","author":"Bolha","year":"2017","journal-title":"Dis Mark."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000437033","article-title":"Metabolomics in the clinical diagnosis of inflammatory bowel disease","volume":"33","author":"De Preter","year":"2015","journal-title":"Digest Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12026-013-8384-0","article-title":"C-reactive protein and the biology of disease","volume":"56","author":"Ansar","year":"2013","journal-title":"Immunol Res."},{"key":"B145","doi-asserted-by":"publisher","first-page":"48487","DOI":"10.1074\/jbc.R400025200","article-title":"C-reactive Protein","volume":"279","author":"Black","year":"2004","journal-title":"J Biol Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clinbiochem.2019.06.009","article-title":"A multicenter evaluation of a point of care CRP Test","volume":"71","author":"Scharnhorst","year":"2019","journal-title":"Clin Biochem"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation."},{"key":"B149","doi-asserted-by":"publisher","first-page":"561428","DOI":"10.1155\/2014\/561428","article-title":"C-reactive protein in human atherogenesis: facts and fiction","volume":"2014","author":"Zimmermann","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B150","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-019-1236-x","article-title":"Longitudinal multi-omics of host-microbe dynamics in prediabetes","volume":"569","author":"Zhou","year":"2019","journal-title":"Nature."},{"key":"B151","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova","year":"2014","journal-title":"Hepatology."},{"key":"B152","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.dld.2017.12.008","article-title":"Serial C-reactive protein measurements in patients treated for suspected abdominal tuberculosis","volume":"50","author":"Sharma","year":"2018","journal-title":"Dig Liver Dis."},{"key":"B153","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","article-title":"Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis","volume":"12","author":"Fagan","year":"1982","journal-title":"Eur J Clin Invest."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1097\/MPG.0000000000001444","article-title":"Correlation of erythrocyte sedimentation rate and C-reactive protein with pediatric inflammatory bowel disease activity","volume":"65","author":"Alper","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B155","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1469-1809.2006.00272.x","article-title":"Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia","volume":"70","author":"Suk","year":"2006","journal-title":"Ann Hum Genet."},{"key":"B156","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2474-15-368","article-title":"How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis","volume":"15","author":"Siemons","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B157","doi-asserted-by":"publisher","first-page":"710915","DOI":"10.1155\/2014\/710915","article-title":"Biomarkers of inflammatory bowel disease","volume":"2014","author":"Fengming","year":"2014","journal-title":"Dis Mark."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood."},{"key":"B159","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"B160","doi-asserted-by":"publisher","first-page":"744","DOI":"10.17235\/reed.2019.5797\/2018","article-title":"The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease","volume":"111","author":"Suarez","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"B161","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/antiox8090351","article-title":"Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease","volume":"8","author":"Bourgonje","year":"2019","journal-title":"Antioxidants"},{"key":"B162","doi-asserted-by":"publisher","first-page":"6517549","DOI":"10.1155\/2019\/6517549","article-title":"Correlation between serological biomarkers and disease activity in patients with inflammatory bowel disease","volume":"2019","author":"Xu","year":"2019","journal-title":"Biomed Res Int."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e17208","DOI":"10.1097\/MD.0000000000017208","article-title":"Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease","volume":"98","author":"Martinez-Fierro","year":"2019","journal-title":"Medicine."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in IBD","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin alphaE and granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology."},{"key":"B166","first-page":"1","article-title":"A noninvasive method to assess mucosal healing in patients* with Crohn's disease","volume":"14","author":"Sandborn","year":"2018","journal-title":"Gastroenterol Hepatol."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz226","article-title":"Soluble blood markers of mucosal healing in inflammatory bowel disease: the future of noninvasive monitoring","author":"Nardone","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"B168","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ecco-jcc\/jjz125","article-title":"The ulcerative colitis response index for detection of mucosal healing in patients treated with anti-tumour necrosis factor","volume":"14","author":"de Bruyn","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B169","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000489010","article-title":"High prevalence of vitamin D deficiency among patients with inflammatory bowel disease","volume":"2","author":"Caviezel","year":"2018","journal-title":"Inflamm Intest Dis."},{"key":"B170","doi-asserted-by":"publisher","first-page":"3275025","DOI":"10.1155\/2018\/3275025","article-title":"A new model based on 25-hydroxyvitamin D3 for predicting active Crohn's disease in chinese patients","volume":"2018","author":"Lin","year":"2018","journal-title":"Mediat Inflamm."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jgh.12324","article-title":"Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study","volume":"28","author":"Lee","year":"2013","journal-title":"J Gastroenterol Hepatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for inflammatory bowel disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENTI","volume":"35","author":"Reinisch","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04827.x","article-title":"Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease","volume":"34","author":"Kiss","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3109\/00365521.2016.1144781","article-title":"Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-\u03b1 antibodies in ulcerative colitis","volume":"51","author":"Morita","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1097\/MIB.0000000000000566","article-title":"Heightened expression of CD39 by regulatory T lymphocytes is associated with therapeutic remission in inflammatory bowel disease","volume":"21","author":"Gibson","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/MEG.0000000000001493","article-title":"Serum gamma-globulin and albumin concentrations predict secondary loss of response to anti-TNFalpha in inflammatory bowel disease patients","volume":"31","author":"Schoenefuss","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"Jurgens","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14423\/SMJ.0000000000000253","article-title":"pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD","volume":"108","author":"Nguyen","year":"2015","journal-title":"South Med J."},{"key":"B182","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","article-title":"Predictors of early response to infliximab in patients with ulcerative colitis","volume":"13","author":"Ferrante","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"B183","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12916-017-0949-7","article-title":"Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease","volume":"15","author":"Bjerrum","year":"2017","journal-title":"BMC Med."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.13641","article-title":"Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis","volume":"43","author":"Choung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/ecco-jcc\/jjw076","article-title":"Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis","volume":"10","author":"Ippolito","year":"2016","journal-title":"J Crohns Colitis."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.crohns.2014.03.009","article-title":"Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease","volume":"8","author":"Rieder","year":"2014","journal-title":"J Crohns Colitis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/jcmm.12869","article-title":"Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition","volume":"20","author":"Zidar","year":"2016","journal-title":"J Cell Mol Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/MIB.0000000000000298","article-title":"Intestinal Fibrosis in Crohn's Disease","volume":"21","author":"Lewis","year":"2015","journal-title":"Inflamm Bowel Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T04:39:25Z","timestamp":1587530365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":188,"alternative-id":["10.3389\/fmed.2020.00123"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00123","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"article-number":"123"}}